CooperCompanies is set to report earnings after market close on Wednesday, with analysts expecting revenue to grow 3.5% year on year, a slowdown from the 5.7% increase recorded in the same quarter last year. The medical device company beat analysts' revenue expectations last quarter, reporting revenues of $1.08 billion, up 7.9% year on year, and also exceeded EPS estimates. Analysts have generally reconfirmed their estimates over the past 30 days, though CooperCompanies has missed Wall Street's revenue estimates multiple times in the last two years. Peers Baxter and Neogen have already reported strong results, with Baxter beating revenue expectations by 6% and Neogen topping estimates by 6%, leading to share price gains of 5.6% and 28.1%, respectively. CooperCompanies shares are down 8.4% over the past month, trading at $70.30, with an average analyst price target of $81.50.
The Cooper Companies, IncEarnings preview: analysts expect revenue growth to slow to 3.5% YoY, with a history of revenue misses, though estimates were reconfirmed.
Baxter International Inc
Neogen Corporation